Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes

References

• Diabetes Programme [webpage on the Internet]World Health Organization Diabetes Programme Available from: http://www.who.int/diabetes/en/Accessed December 1, 2015
   Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors CollaborationSarwarNGaoPDiabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesLancet201037597332215222220609967
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors CollaborationDi AngelantonioEKaptogeSAssociation of cardiometabolic multimorbidity with mortalityJAMA20153141526026151266
   PubMed Web of Science ®Google Scholar
• FDA [webpage on the Internet]FDA Approves Jardiance to Treat Type 2 Diabetes2014 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htmAccessed December 15, 2015
   Google Scholar
• Abdul-GhaniMADeFronzoRALowering plasma glucose concentration by inhibiting renal sodium-glucose cotransportJ Intern Med2014276435236324690096
   PubMed Web of Science ®Google Scholar
• WrightEMHirayamaBALooDFActive sugar transport in health and diseaseJ Intern Med20072611324317222166
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMADeFronzoRANortonLNovel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humansDiabetes201362103324332824065789
   PubMed Web of Science ®Google Scholar
• GremplerRThomasLEckhardtMEmpagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitorsDiabetes Obes Metab2012141839021985634
   PubMed Web of Science ®Google Scholar
• MerovciASolis-HerreraCDanieleGDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJ Clin Invest2014124250951424463448
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitorClin Pharmacokinet201453321322524430725
   PubMed Web of Science ®Google Scholar
• SemanLMachaSNehmizGEmpagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjectsClin Pharm Drug Dev201322152161
   PubMed Web of Science ®Google Scholar
• MachaSJungnikAHohlKHobsonDSalsaliAWoerleHJEffect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteersInt J Clin Pharmacol Ther2013511187387924152604
   PubMed Web of Science ®Google Scholar
• SarashinaAKoiwaiKSemanLJSafety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjectsDrug Metab Pharmacokinet201328321321923149871
   PubMed Web of Science ®Google Scholar
• HeiseTSeewaldt-BeckerEMachaSSafety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetesDiabetes Obes Metab201315761362123356556
   PubMed Web of Science ®Google Scholar
• HeiseTSemanLMachaSSafety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitusDiabetes Ther20134233134523838841
   PubMed Web of Science ®Google Scholar
• KanadaSKoiwaiKTaniguchiASarashinaASemanLWoerleHJPharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks’ treatment with empagliflozin in Japanese patients with type 2 diabetes mellitusJ Diabetes Investig201346613617
   PubMed Web of Science ®Google Scholar
• Coll-de-TueroGMata-CasesMRodriguez-PoncelasAChronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean areaBMC Nephrol2012138722905926
   PubMed Web of Science ®Google Scholar
• MachaSMattheusMHalabiAPinnettiSWoerleHJBroedlUCPharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairmentDiabetes Obes Metab201416321522223859488
   PubMed Web of Science ®Google Scholar
• SarashinaAUekiKSasakiTEffect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitusClin Ther201436111606161525199997
   PubMed Web of Science ®Google Scholar
• MachaSRosePMattheusMPharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairmentDiabetes Obes Metab201416211812323859534
   PubMed Web of Science ®Google Scholar
• RiggsMMStaabASemanLPopulation pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetesJ Clin Pharmacol201353101028103823940010
   PubMed Web of Science ®Google Scholar
• FerranniniESemanLSeewaldt-BeckerEHantelSPinnettiSWoerleHJA phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetesDiabetes Obes Metab201315872172823398530
   PubMed Web of Science ®Google Scholar
• KadowakiTHanedaMInagakiNEmpagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trialAdv Ther201431662163824958326
   PubMed Web of Science ®Google Scholar
• KadowakiTHanedaMInagakiNEfficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group studyAdv Ther201532430631825845768
   PubMed Web of Science ®Google Scholar
• RodenMWengJEilbrachtJEmpagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialLancet Diabetes Endocrinol20131320821924622369
   PubMed Web of Science ®Google Scholar
• TikkanenINarkoKZellerCEmpagliflozin reduces blood pressure in patients with type 2 diabetes and hypertensionDiabetes Care201538342042825271206
   PubMed Web of Science ®Google Scholar
• CavalotFPagliarinoAValleMPostprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes StudyDiabetes Care201134102237224321949221
   PubMed Web of Science ®Google Scholar
• CavalotFPetrelliATraversaMPostprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes StudyJ Clin Endocrinol Metab200691381381916352690
   PubMed Web of Science ®Google Scholar
• MonnierLMasEGinetCActivation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetesJAMA2006295141681168716609090
   PubMed Web of Science ®Google Scholar
• NishimuraRTanakaYKoiwaiKEffect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week studyCardiovasc Diabetol2015141125633683
   PubMed Web of Science ®Google Scholar
• LaffelLKetone bodies: a review of physiology, pathophysiology and application of monitoring to diabetesDiabetes Metab Res Rev199915641242610634967
   PubMed Web of Science ®Google Scholar
• ArakiETanizawaYTanakaYLong-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitusDiabetes Obes Metab201517766567425772548
   PubMed Web of Science ®Google Scholar
• RosenstockJSemanLJJelaskaAEfficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemiaDiabetes Obes Metab201315121154116023906374
   PubMed Web of Science ®Google Scholar
• FerranniniEBerkAHantelSLong-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetesDiabetes Care201336124015402124186878
   PubMed Web of Science ®Google Scholar
• HaringHUMerkerLSeewaldt-BeckerEEmpagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care20143761650165924722494
   PubMed Web of Science ®Google Scholar
• MerkerLHaringHUChristiansenAVEmpagliflozin as add-on to metformin in people with Type 2 diabetesDiabet Med201532121555156726031566
   PubMed Web of Science ®Google Scholar
• RidderstraleMAndersenKRZellerCComparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trialLancet Diabetes Endocrinol20142969170024948511
   PubMed Web of Science ®Google Scholar
• HaringHUMerkerLSeewaldt-BeckerEEmpagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care201336113396340423963895
   PubMed Web of Science ®Google Scholar
• HaeringHUMerkerLChristiansenAVEmpagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetesDiabetes Res Clin Pract20151101829026324220
   PubMed Web of Science ®Google Scholar
• KovacsCSSeshiahVSwallowREmpagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trialDiabetes Obes Metab201416214715823906415
   PubMed Web of Science ®Google Scholar
• FerranniniEMuscelliEFrascerraSMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJ Clin Invest2014124249950824463454
   PubMed Web of Science ®Google Scholar
• FriedrichCMetzmannKRosePMattheusMPinnettiSWoerleHJA randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteersClin Ther2013351A33A4223328275
   PubMed Web of Science ®Google Scholar
• LewinADeFronzoRAPatelSInitial combination of empagliflozin and linagliptin in subjects with type 2 diabetesDiabetes Care201538339440225633662
   PubMed Web of Science ®Google Scholar
• DeFronzoRALewinAPatelSCombination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metforminDiabetes Care201538338439325583754
   PubMed Web of Science ®Google Scholar
• RossSThamerCCescuttiJMeinickeTWoerleHJBroedlUCEfficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trialDiabetes Obes Metab201517769970225827441
   PubMed Web of Science ®Google Scholar
• RosenstockJJelaskaAZellerCImpact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trialDiabetes Obes Metab2015171093694826040302
   PubMed Web of Science ®Google Scholar
• RosenstockJJelaskaAFrappinGImproved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetesDiabetes Care20143771815182324929430
   PubMed Web of Science ®Google Scholar
• HolmanRRSourijHCaliffRMCardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesLancet201438399332008201724910232
   PubMed Web of Science ®Google Scholar
• HaywardRAReavenPDEmanueleNVVADT InvestigatorsFollow-up of glycemic control and cardiovascular outcomes in type 2 diabetesN Engl J Med20153731097826332555
   PubMed Web of Science ®Google Scholar
• HongJZhangYLaiSEffects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery diseaseDiabetes Care20133651304131123230096
   PubMed Web of Science ®Google Scholar
• MonamiMDicembriniINardiniCFiordelliIMannucciEEffects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trialsDiabetes Obes Metab2014161384723829656
   PubMed Web of Science ®Google Scholar
• SeongJMChoiNKShinJYDifferential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort studyPLoS One2015105e012428725992614
   PubMed Web of Science ®Google Scholar
• ChiltonRTikkanenICannonCP4b.02: the sodium glucose cotransporter 2 inhibitor empagliflozin reduces blood pressure and markers of arterial stiffness and vascular resistance in type 2 diabetesJ Hypertens201533suppl 1e53
   Google Scholar
• ChiltonRTikkanenICannonCPEffects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesDiabetes Obes Metab201517121180119326343814
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• McMurrayJJGersteinHCHolmanRRPfefferMAHeart failure: a cardiovascular outcome in diabetes that can no longer be ignoredLancet Diabetes Endocrinol201421084385124731668
   PubMed Web of Science ®Google Scholar
• NicholsGAGullionCMKoroCEEphrossSABrownJBThe incidence of congestive heart failure in type 2 diabetes: an updateDiabetes Care20042781879188415277411
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• NestoRWBellDBonowROThiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003Circulation2003108232941294814662691
   PubMed Web of Science ®Google Scholar
• InzucchiSEZinmanBWannerCSGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trialsDiab Vasc Dis Res20151229010025589482
   PubMed Web of Science ®Google Scholar
• CheesemanCSolute carrier family 2, member 9 and uric acid homeostasisCurr Opin Nephrol Hypertens200918542843219593129
   PubMed Web of Science ®Google Scholar
• KanbayMJensenTSolakYUric acid in metabolic syndrome: from an innocent bystander to a central playerEur J Intern Med2016293826703429
   PubMed Web of Science ®Google Scholar
• UchidaSChangWXOtaTTargeting uric acid and the inhibition of progression to end-stage renal disease-a propensity score analysisPLoS One20151012e014550626700005
   PubMed Web of Science ®Google Scholar
• BarnettAHMithalAManassieJEfficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trialLancet Diabetes Endocrinol20142536938424795251
   PubMed Web of Science ®Google Scholar
• BrunkDEmpagliflozin benefited type 2 diabetes patients with CKDClinical Endocrinology News Digital Network2015
   Google Scholar
• CherneyDCooperMTikkanenI4b.01: contrasting influences of renal function on blood pressure and HbA1C reductions with empagliflozin in patients with type 2 diabetes and hypertensionJ Hypertens201533Suppl 1e5326102847
   PubMed Web of Science ®Google Scholar
• VivianEMSodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsDrugs Context2014321226425598831
   PubMedGoogle Scholar
• BolinderJLjunggrenÖJohanssonLDapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metforminDiabetes Obes Metab201416215916923906445
   PubMed Web of Science ®Google Scholar
• CefaluWTLeiterLAYoonKHEfficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialLancet2013382989694195023850055
   PubMed Web of Science ®Google Scholar
• TaylorSIBlauJERotherKISGLT2 inhibitors may predispose to ketoacidosisJ Clin Endocrinol Metab201510082849285226086329
   PubMed Web of Science ®Google Scholar
• TaylorSIBlauJERotherKIPossible adverse effects of SGLT2 inhibitors on boneLancet Diabetes Endocrinol20153181025523498
   PubMed Web of Science ®Google Scholar
• CherneyDZPerkinsBASoleymanlouNRenal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitusCirculation2014129558759724334175
   PubMed Web of Science ®Google Scholar
• SchernthanerGMogensenCESchernthanerGHThe effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal systemDiab Vasc Dis Res201411530632325116004
   PubMed Web of Science ®Google Scholar
• VallonVGerasimovaMRoseMASGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita miceAm J Physiol Renal Physiol20143062F194F20424226524
   PubMed Web of Science ®Google Scholar